Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]
¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL#Linfoma#Networking#Hem… https://t.co/unHn9lLqeQ
Add this session to your ASH schedule 📅 on Monday 8th December at 12:30pm at #ASH2025 Very excited to chair this session with amazing colleagues from across Latin America to discuss advances and challenges in leukemia. Looking forward to an inspiring conversation!
🇲🇽🇧🇷🇦🇷🇨🇱🇨🇴🇵🇪
Honrada de ser reconocida por @ash_hematology con un Abstract Achievement Award.
Cada logro en investigación es fruto del trabajo colaborativo y de la inspiración de pacientes, mentores y colegas.
¡Nos vemos en #ASH25!
#Hematología#Investigación#Gratitud
CONGRESS | #18ICML | PRESENTATION
Kate Cwynarski @CwynKate@uclh presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75).
Long-term follow-up results demonstrate durable remissions (7-year PFS, 64%) in patients who proceeded to TT-ASCT. The 7-year PFS rates were 52%, 33%, and 11% for patients with de novo SCNSL, isolated CNS relapse, and synchronous CNS relapse, respectively.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedicalCongress
@GabrielBoric@ximenaguilera Estimado Presidente. Soy Médico y trabajo en el sistema publico . Creo humildememte que la salud publica mejoraria drasticamente con 1 sola medida: que todas las autoridades : ministros ,parliamentarios, jueces, e incluso ud, al asumir deban atenderse en el Sistema publico.
👌ECHELON-3 🆕️ is the first randomized, placebo-controlled, phase 3 study to demonstrate overall survival benefit in a
contemporary population of patients with R/R DLBCL who have received 2or more prior lines of systemic therapy
💊BV+Len+R met its primary objective
#SOHO2024
A new study published in @TheLancetHaem found that epcoritamab was associated with an ORR of 82% in patients with R/R follicular #lymphoma📝
More news: https://t.co/xVXjzsqQhA
#lymsm#MedNews#MedEd
👏👏 Super kudos to @pmcancercentre @rkridel for this outstanding translational work in follicular #lymphoma.
From 713 tumor tissue samples (eg, E4402, E2408 & GALLIUM), 5 genetic subtypes discovered and a/w clinicopath findings & pt outcomes.
👉👉 SEE: https://t.co/xJ1BrUCSSB
Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma: Expert Review of Hematology: Vol 0, No 0 - Get Access https://t.co/OUTPIxccsP
Front line treatment of Hodgkin Lymphoma with PET-adapted BrECADD vs escBEACOPP.
BrECADD wins the day. Can it be beaten…? #lymsm
https://t.co/bAA5PKDVSo
SPOTLIGHT REVIEW
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma
Megan Melody
Leo I. Gordon
@Haematologica
https://t.co/OZy8YHaXpl
Zanubrutinib, obinutuzumab, and venetoclax (the BOVen regimen) was safe and produced responses in older patients with #MCL, according to data from the phase 2 trial. #EHA24#EHA2024 | @MSK_DeptOfMed
https://t.co/KsdK84UEMK
Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL!
26 y 27 de Julio 2024
Double tree by Hilton , av. Kennedy 4422, Vitacura
Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!
Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]
¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL#Linfoma#Networking#Hematología
¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)!
Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.